Osisko Gold grabs Orion’s metals portfolio in $1.13 billion deal

Shares in Canada’s Osisko Gold Royalties (TSX, NYSE:OR) jumped Monday following the company’s decision to buy a precious metals portfolio from US private equity firm Orion Mine Finance Group for Cdn$1.13 billion (about $834 million).

The portfolio consists of 74 royalties, streams and precious metal offtakes, and its acquisition will result in Osisko holding a total of 131 royalties and streams, including 16 revenue-generating assets, the company said in a statement.

Osisko’s stoke was trading up 9.7% to Cdn$15.80 in Toronto and almost 9.9% higher in New York to $11.72 at around 11:15 ET on the news of the acquisition, which will help the company expand its diamond, gold and silver asset base.

Osisko, created in June 2014 following the acquisition of Osisko Mining by Agnico Eagle Mines and Yamana Gold, said it will pay Orion $675-million in cash and the remaining $450-million in company shares for the assets.

The transaction gives the Canadian company a 9.6% diamond stream on the Renard diamond mine and a 4% gold and silver stream on the Brucejack gold and silver mine, both in Canada, in addition to a 100% silver stream on the Mantos Blancos copper mine in Chile.

But its flagship assets continue to be the 5% net-smelter-return royalty on the Malartic mine, described as Canada’s largest producing gold mine, and its 2% to 3.5% NSR royalty on the Éléonore gold mine.

Osisko is a royalty company, which means that it seeks agreements giving it the right to a share of income from mines operated by other companies.

Source: www.mining.com

Macquarie’s Brian Bagnell Thinks Manitok is Trading Cheaply

SciClone and BTG Announce That DC Bead(R) Has Been Approved by China Food and Drug Administration

【Life Science】Abivax tees up a $49M IPO to get its hep B shot into Phase III

Avino closes U.S. brokered public offering

Raging River Exploration Inc. Announces Closing of Corporate Acquisition of Rock Energy Inc.

MGX Minerals Reports up to 99.9% SiO2 Results from Silicon Properties

Japan's Takeda puts down $65M in rare disease therapies deal with Ultragenyx

FDA approves Baxalta's treatment for common bleeding disorder

Upcoming Events More